{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-010108","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.812018+00:00","generated_at":"2026-06-17T12:50:43.347695+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Viking's VK2735 Phase 1 shows up to 7.8% mean weight loss; Phase 2 obesity trial planned mid-2023","bullets":["Placebo-adjusted mean weight loss up to 6.0% (7.8% from baseline) after 28 days of weekly dosing.","No hypoglycemia reported; 98% of adverse events mild/moderate; one SAE (gallstone obstruction) in a subject with history of cholelithiasis.","VK2735 half-life ~170-250 hours; plans to evaluate higher doses with longer titration in Phase 2.","Phase 2 trial in obesity expected to initiate in mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-010108","json":"https://secwatch.observer/filing/0000950170-23-010108.json","markdown":"https://secwatch.observer/filing/0000950170-23-010108.md","text":"https://secwatch.observer/filing/0000950170-23-010108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000095017023010108/0000950170-23-010108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000095017023010108/vktx-20230328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T12:50:43.347695+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}